SOURCE: NuGene International, Inc.

NuGene International, Inc.

April 13, 2015 08:45 ET

NuGene International, Inc. Adds Dr. Mitchell Goldman to Advisory Board

Co-Founder of SkinMedica® Provides Additional Cosmetic Dermatology Expertise

IRVINE, CA--(Marketwired - Apr 13, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has added Dr. Mitchell Goldman, noted dermatologist and co-founder of SkinMedica®, to its advisory board effective April 1, 2015.

Dr. Goldman's expertise in cosmetic dermatology includes laser treatments, sclerotherapy, injectables, liposculpture and general dermatology. He lectures both nationally and internationally on innovative surgical and treatment techniques. He is the co-founder of SkinMedica, a company that offers skin care products that include skin rejuvenators such as vitamins E and C, retinol, tea tree oil and salicylic acid. SkinMedica was acquired by Allergan in 2012.

"We feel very fortunate to have attracted Dr. Goldman to the NuGene team," stated NuGene CEO Ali Kharazmi when announcing the new advisory board member. "His experience in our particular field, combined with his great accomplishments in the past, will bring additional critical expertise and insight to our product development and market focus. As a company built upon science, we depend heavily on the collective wisdom of our management team and advisory board as the company develops."

Dr. Goldman is an expert in the areas of dermatology, phlebology, laser surgery, and liposuction. He is a Fellow of the American Society for Dermatologic Surgery, the American Academy of Dermatology, the American Academy of Cosmetic Surgery, the American Society of Anti-Aging Medicine, the American College of Phlebology and the American Society for Laser Medicine and Surgery. Dr. Goldman was Board Certified as a Diplomat of the American Board of Dermatology in 1986 and by the American Board of Cosmetic Surgery in 2002. Dr. Goldman serves as Scientific Advisor at Avidas Pharmaceuticals LLC. He is a Clinical Professor of Dermatology/Medicine, University of California, San Diego.

As a prolific scholar, Dr. Goldman has authored and edited over 300 peer-reviewed publications and book chapters. In addition, he has co-authored 18 highly recognized medical textbooks on cosmetic and laser surgery, dermatology, sclerotherapy, ambulatory phlebectomy and cellulite, several of which are considered definitive medical texts in their respective fields. Moreover, Dr. Goldman lectures both nationally and internationally on innovative surgical treatment techniques.

In addition, Dr. Goldman has a distinguished record of editorial activities including currently serving on the editorial boards of Aesthetic Medicine, the Australian and New Zealand Journal of Phlebology, the Journal of Cutaneous Laser Therapy, and Phlebology; as the International Editor for Dermatologica Sinica; Senior Editor for the Journal of Drugs in Dermatology; Assistant Editor for the Journal of Cosmetic Dermatology and Dermatologic Surgery; and Associate Editor for Venous Digest. Moreover, Dr. Goldman is a peer-reviewer for multiple journals such as the Journal of the European Academy of Dermatology and Venereology, the Journal of Plastic and Reconstructive Surgery, the European Journal of Vascular and Endovascular Surgery, Aesthetic Surgery Journal, the International Journal of Cosmetic Surgery, the Archives of Dermatology, Lasers in Surgery and Medicine, and the Journal of the American Academy of Dermatology.

Dr. Goldman is a member of over 30 well-respected national and regional societies including serving as the Founder and Past President of the American College of Phlebology; Past President of the San Diego Dermatological Society; Past President of the Sonoran Dermatology Society; and has served on the Board of Directors for the American Society for Dermatologic Surgery, Pacific Dermatology Association, American Venous Forum, the California Academy of Cosmetic Surgery and the Board of Governors for Stanford University School of Medicine. In addition, Dr. Goldman is a member of the American Academy of Dermatology, American College of Phlebology, American Dermatological Association, the Noah Worcester Dermatology Society, the Women's Dermatology Society, the California Society of Dermatology, the Aerospace Medical Association, the American Society of Liposuction Surgery, the American Academy of Cosmetic Surgery, the Cosmetic Surgery Foundation, to name a few.

Throughout his impressive professional career, Dr. Goldman has been the recipient of numerous prestigious awards and honors including the President's Award from the American Society for Dermatologic Surgery for outstanding contribution in teaching and research; the American Academy of Cosmetic Surgery's "21st Century Achievement Award" for outstanding contribution to cosmetic surgery in the 21st century; Phi Beta Kapp Epsilon of Massachusetts; as well as being recognized for distinction work in biology from Boston University.

Dr. Goldman received his Doctor of Medicine from Stanford University. He completed his internship at the University of California, San Diego and his residency with specialization in dermatology at the University of California, Los Angeles. Dr. Goldman also holds a Bachelor of Arts degree in biology from Boston University.

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has two patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015 and in its Annual Report on Form 10-K filed with the Commission on March 30, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

*News and content distribution services by 1-800-PublicRelations, Inc. (

Contact Information

  • Investor/ Media Relations:
    Chris Rosgen
    Capital Market Relations